Oral Prophylaxis with Berotralstat (BCX7353) Reduces Use of Standard of Care (SOC) On-demand Medication in Patients with Hereditary Angioedema (HAE): APeX-2 Study Results

https://doi.org/10.1016/j.jaci.2019.12.632Get rights and content

Section snippets

Rationale

Berotralstat is a once-daily oral inhibitor of plasma kallikrein in development for prophylaxis of HAE. The Phase 3, randomized, double-blind, placebo-controlled APeX-2 study (NCT03485911) evaluated the efficacy of berotralstat over a 24-week period. The use of SOC on-demand medications during this study was evaluated.

Methods

Subjects with HAE Type 1/2 with ≥2 attacks in the 14-56 day baseline period were randomized 1:1:1 to receive berotralstat 150mg or 110mg or placebo for 24 weeks. Subjects were to treat any HAE attacks occurring on study in accordance with their usual acute treatment plan. Investigator-confirmed HAE attacks and SOC on-demand medication use over 24 weeks were analyzed.

Results

The HAE attack rate was significantly lower in both berotralstat dose groups compared to placebo (150 mg, -44.2%, p<0.001; 110mg, -30.0%, p=0.024, primary endpoint). The rate of attacks requiring treatment was also significantly lower in both berotralstat dose groups compared to placebo (150mg, -49.2%, nominal p<0.001; 110mg, -36.9%, nominal p=0.015). The rate of use of SOC on-demand medications was significantly reduced in both the 150mg (-53.6%, nominal p<0.001) and the 110mg (-46.3%, nominal

Conclusions

Berotralstat at 150mg QD significantly reduced the rate of attacks, attacks requiring treatment, and to a greater extent, the rate of SOC on-demand medication use relative to placebo in the APeX-2 study, suggesting reduced attack severity on berotralstat. These represent key features of successful HAE prophylaxis.

References (0)

Cited by (0)

View full text